Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Gene Therapy For Parkinson’s Disease Market Set To Climb From $0.81 Billion In 2026 To $2.04 Billion By 2030
The market for gene therapy targeting Parkinson’s disease has experienced significant expansion in recent years. This market is projected to expand from $0.64 billion in 2025 to $0.81 billion in 2026, at a compound annual growth rate (CAGR) of 26.3%. The growth observed in the historic period can be attributed to several factors, including advancements in viral vector engineering, a deeper understanding of Parkinson’s disease pathology, increased funding for neuroscience research, the availability of enhanced delivery technologies, and promising outcomes from initial clinical trials.
The gene therapy sector for Parkinson’s disease is anticipated to undergo substantial expansion in the upcoming years. Its valuation is predicted to reach $2.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.0%. This projected growth can be attributed to several factors including increased funding for neurodegenerative disease treatments, the rising adoption of personalized gene therapy approaches, the expansion of late-stage clinical trial pipelines, an escalating demand for disease-modifying therapies, and advancements in minimally invasive delivery methods. Prominent trends for the forecast period encompass the increasing development of viral vector-based therapies, a growing focus on dopamine restoration strategies, the expanding application of neurotrophic factor gene delivery, the proliferation of precision intracerebral delivery techniques, and an elevated emphasis on long-term therapeutic efficacy.
Get A Free Sample Report With In-Depth Market Insights:
Gene Therapy For Parkinson’s Disease Market Growth Factors: What’s Supporting Expansion?
The gene therapy for Parkinson’s disease market is anticipated to expand propelled by the increasing focus on personalized medicine. This medical strategy customizes treatment and prevention plans based on an individual’s genetic makeup, lifestyle, and environment. The rising demand for targeted therapies, which improve treatment effectiveness and minimize adverse side effects, is fueling the growing interest in personalized medicine. In this context, gene therapy for Parkinson’s disease delivers tailored genetic modifications to restore dopamine function and address unique patient-specific disease mechanisms. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, stated that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, representing a notable increase from the 6 approvals in 2022. Therefore, the surging interest in personalized medicine is a primary driver for the growth of the gene therapy for Parkinson’s disease market.
Gene Therapy For Parkinson’s Disease Market Segments: Where Is Growth Concentrated?
The gene therapy for parkinson’s disease market covered in this report is segmented –
1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy
2) By Vector Type: Viral Vectors, Non-Viral Vectors
3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes
4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors
2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy
Gene Therapy For Parkinson’s Disease Market Industry Trends: What’s Reshaping Demand?
Within the gene therapy for Parkinson’s disease market, major companies are actively developing more precise therapies, such as regenerative medicine advanced therapy, aiming to improve neuronal survival, restore dopamine function, and offer long-lasting disease-modifying advantages for patients. Regenerative medicine advanced therapy (RMAT) is a specific designation from the United States Food and Drug Administration (FDA), granted to regenerative medicine products like cell therapies, gene therapies, and tissue-engineered products, designed to treat, modify, reverse, or cure serious or life-threatening conditions. For example, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy company, introduced AB-1005, an investigational AAV2-GDNF gene therapy that received FDA regenerative medicine advanced therapy (RMAT) designation. This designation, intended to accelerate the development and review of promising therapies, was provided based on data submitted by AskBio, including clinical evidence from its Phase Ib open-label, uncontrolled trial, which demonstrated AB-1005’s potential to slow disease progression and enhance motor function in Parkinson’s patients.
Gene Therapy For Parkinson’s Disease Market Key Participants And Competitive Landscape
Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.
View The Full Gene Therapy For Parkinson’s Disease Market Report:
Gene Therapy For Parkinson’s Disease Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model